Zhejiang Int'l Group Co

Zhejiang Int'l Group Co Long-term Debt

The Long-Term Debt of Zhejiang Int'l Group Co (000411.SZ) as of Nov 4, 2026 is 239.16 M CNY. In the previous year, Long-Term Debt was 447.06 M CNY — a change of -46.50% (lower).

Long-term Debt

239.16 MCNY

YoY

-46.50%

Last updated:

Long-Term Debt of Zhejiang Int'l Group Co is 2025 239.16 M CNY. Long-Term Debt of Zhejiang Int'l Group Co was 2024 447.06 M CNY. It decreases by -46.50% lower compared to the previous year.

The Zhejiang Int'l Group Co Long-term Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Long-term Debt
Date
Long-term Debt
Jan 1, 2018
414.20 M CNY
Jan 1, 2019
250.00 M CNY
Jan 1, 2020
550.00 M CNY
Jan 1, 2021
810.20 M CNY
Jan 1, 2022
512.58 M CNY
Jan 1, 2023
521.42 M CNY
Jan 1, 2024
447.06 M CNY
Jan 1, 2025
239.16 M CNY
The Zhejiang Int'l Group Co Long-term Debt history
YEARLong-term DebtYoY
239.16 MCNY-46.50%
447.06 MCNY-14.26%
521.42 MCNY+1.72%
512.58 MCNY-36.73%
810.20 MCNY+47.31%
550.00 MCNY+120.00%
250.00 MCNY-39.64%
414.20 MCNY+386.00%
85.23 MCNY+243.57%
24.81 MCNY+224.01%
7.66 MCNY-52.73%
16.20 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Zhejiang Int'l Group Co Stock analysis

What does Zhejiang Int'l Group Co do? Zhejiang Int'l Group Co., Ltd. generates revenue by wholesaling and retailing pharmaceuticals and medical devices. The company buys products from pharmaceutical manufacturers or suppliers and distributes them to distributors, medical institutions, and pharmacies. It also sells directly to consumers through retail terminals. The firm operates exclusively within Mainland China, serving a broad customer base across the healthcare sector. The business model relies on purchasing products from manufacturers or suppliers, then reselling them through wholesale channels to medical institutions and pharmacies, or via retail terminals to end consumers. This dual-channel approach allows the company to reach both institutional and individual customers without direct manufacturing involvement. Mainland China represents the sole market for all its operations. Zhejiang Int'l Group Co., Ltd. focuses on pharmaceutical and medical device distribution, targeting distributors, medical institutions, and pharmacies as key wholesale clients. Retail sales are directed toward consumers through its own retail terminals. The company does not engage in manufacturing, instead acting as a middleman between producers and end users within the Chinese healthcare market. Zhejiang Int'l Group Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Zhejiang Int'l Group Co stock

Long-Term Debt of Zhejiang Int'l Group Co is 239.16 M CNY in 2025.

Long-Term Debt of Zhejiang Int'l Group Co changed from 447.06 M CNY to 239.16 M CNY, representing a -46.50% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Long-Term Debt Zhejiang Int'l Group Co since 2006 – with annual values, charts, and detailed analysis.

Long-term debt represents obligations due after one year. It is a key component of a company's capital structure and leverage.

Long-Term Debt's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Long-Term Debt's Zhejiang Int'l Group Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Zhejiang Int'l Group Co

All Key Metrics — Zhejiang Int'l Group Co